SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Britain Courts Anthropic Amid US Defense Department Dispute 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
SOUTH SAN FRANCISCO, Calif., July 24, 2017 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, July 27, 2017 at 2:00 p.m. Eastern Time to discuss corporate updates and financial results for the second quarter ended June 30, 2017.
The call can be accessed by dialing (844) 269-7720 (U.S. and Canada) or (574) 990-1148 (international), and entering passcode 51914278.
To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly-experienced cancer drug development organization committed to improving the lives of people with cancer. Currently, the company is focused on advancing its novel kinase-inhibitor pipeline, which includes its proprietary non-covalent BTK-inhibitor, SNS-062.
For additional information on Sunesis, please visit http://www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
Investor and Media Inquiries: Maeve Conneighton Argot Partners 212-600-1902 Dan Swisher Sunesis Pharmaceuticals Inc. 650-266-3715
